Immunome (NASDAQ:IMNM) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital initiated coverage on shares of Immunome (NASDAQ:IMNM) in a report published on Tuesday morning,Benzinga reports. The brokerage issued an outperform rating and a $20.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Monday. Piper Sandler decreased their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $27.17.

Immunome Stock Performance

IMNM stock opened at $8.73 on Tuesday. The firm has a market cap of $696.45 million, a price-to-earnings ratio of -1.08 and a beta of 1.93. The firm has a 50-day simple moving average of $10.09 and a two-hundred day simple moving average of $11.89. Immunome has a one year low of $8.39 and a one year high of $26.70.

Insiders Place Their Bets

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction on Friday, January 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. This represents a 28.87 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Immunome

A number of institutional investors have recently bought and sold shares of IMNM. Enavate Sciences GP LLC purchased a new position in Immunome during the 4th quarter worth approximately $36,939,000. JPMorgan Chase & Co. raised its position in Immunome by 2,540.4% during the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after buying an additional 624,045 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the period. Granahan Investment Management LLC acquired a new stake in shares of Immunome during the 4th quarter worth approximately $3,337,000. Finally, Renaissance Technologies LLC grew its stake in shares of Immunome by 2,696.5% during the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock worth $3,356,000 after purchasing an additional 304,700 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.